公开(公告)号：US20210177987A1

公开(公告)日：2021-06-17

申请号：US16760373

申请日：2018-11-01

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Steen LISBY

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/32 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395 ,  A61P35/04

Abstract: The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).

公开(公告)号：US20190315880A1

公开(公告)日：2019-10-17

申请号：US16367933

申请日：2019-03-28

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/30 ,  A61K47/68 ,  C07K16/36 ,  A61K45/06

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

公开(公告)号：US20190233522A1

公开(公告)日：2019-08-01

申请号：US16316000

申请日：2017-07-07

Applicant: GENMAB A/S

Inventor： Ulf FORSSMANN ,  Steen LISBY ,  Nedjad LOSIC

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/kg to about 2.0 mg/kg of the ADC once a week for three consecutive weeks followed by a one week resting period without any administration of the ADC so that each cycle time is 28 days including the resting period.

公开(公告)号：US20170173151A1

公开(公告)日：2017-06-22

申请号：US15366791

申请日：2016-12-01

Applicant: GENMAB A/S

Inventor： Sandra VERPLOEGEN ,  Marije OVERDIJK ,  Riemke van DIJKHUIZEN ,  Willem Karel BLEEKER ,  Patrick VAN BERKEL ,  Paul PARREN ,  Steen LISBY

IPC: A61K39/395

CPC classification number: A61K39/39541 ,  A61K31/7088 ,  A61K35/17 ,  A61K35/76 ,  A61K38/162 ,  A61K38/19 ,  A61K39/39533 ,  A61K39/39566 ,  A61K45/06 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  A61K2121/00 ,  C07K16/18 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.